• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Scientist and Chinese biotech targeted by Beam in secrets suit
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.
Careers
Clifford Chance recruits new head of Asia-Pac
29 September 2026   As partner and head of IP for the region, the Hong Kong-based hire brings extensive experience advising on the IP aspects of complex corporate transactions and investments.
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Beyond the primary patent: How pharma can build competitive barriers
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook
Brown Rudnick lands largest lateral IP team hire in firm history
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
‘Blatant imitation’: Indian court blocks copycat pharma branding
Kirkland & Ellis adds leading barrister in London
Kilpatrick adds tech patent litigator and China expert to Chicago office

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin